-- Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP53 mutation status in patients age 55 and above with high-risk active ...

In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...

Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study. This is an ASCO Meeting ...

TP53 mutation (MT) in epidermal growth factor receptor (EGFR) -MT non–small cell lung cancer (NSCLC) is associated with poor response to targeted therapy; however, its impact on survival is not ...

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...

Brukinsa showed superior PFS and ORR compared to Rituxan in CLL/SLL patients, with a 71% risk reduction in progression or death. Brukinsa's efficacy was consistent across various risk factors, ...

A sperm donor whose genetic material was used to conceive at least 67 children across Europe unknowingly carried a rare cancer-causing gene mutation, and now 10 of those children have developed cancer ...